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ABSTRACT 
 Clostridium difficile infection (CDI) is a major hospital-acquired diarrhea that can 
cause life-threatening complications such as pseudomembranous colitis. CDI is caused by 
colonization of host with C. difficile, a Gram positive, anaerobic bacterium known to 
produce toxins that cause disease. Normally, the gut microbiota protects the host from 
CDI, but disruption of the microbial composition through antibiotic treatment can leave 
one vulnerable for CDI. To date, no vaccines for preventing CDI are available.  
 In this study, the potential of antibodies directed against specific surface 
molecules of C. difficile to block bacterial adherence to host gut epithelial cells was 
studied, in hopes for developing a vaccine that could prevent colonization and disease. 
Antibodies against recombinant FliD (flagellar cap protein), HMW SLP (surface-
associated protein), and Cwp84 (cysteine protease) were generated in rabbits and tested 
for their ability to reduce C. difficile adherence to Caco-2 BBE cells, a human colon-
derived epithelial cell line. In this model, the antibodies against target molecules did not 
significantly decrease C. difficile adherence, although the target molecules had been 
found to be adhesins in the literature using other models. Thus, these data suggest that 
blocking of C. difficile adherence to epithelial cells using antibodies against adherence-
associated surface molecules may be assay-dependent, highlighting a need to develop 
other models that can effectively simulate the in vivo conditions of CDI pathogenesis.  
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CHAPTER ONE 
 
REVIEW OF LITERATURE 
 
Introduction 
  Clostridium difficile (C. difficile) is a Gram positive, anaerobic bacterium that 
causes diarrhea and in severe cases, pseudomembranous colitis
1
. C. difficile is able to 
form spores that are extremely durable and can contaminate various surfaces including 
those within healthcare environments
2
. The spores can be ingested by people coming in 
contact with the spore-contaminating surfaces, and the bacteria can then colonize the gut 
if the intestinal microbiota is already disrupted
3
. Since antibiotics, the treatment of choice 
for a variety of bacterial infectious diseases in modern medicine, cause disruptions in the 
composition of the host microbiota, people undergoing antibiotic therapy are often at 
increased risk for C. difficile infection (CDI)
4
. Since the use of antibiotics is common in 
various healthcare settings today, many of the CDI cases are known to be healthcare-
associated
5
. Although the major risk factor for contracting CDI is the use of antibiotics, 
the latest treatment recommendation for CDI is still antibiotic therapy using 
metronidazole or oral vancomycin in severe cases
6
. Consequently, a major problem with 
CDI is that about 12-25% of patients undergoing CDI treatment suffer from recurrent 
disease when treatment is stopped
3
. Thus, novel approaches to treat CDI are needed.
2 
 
 Several new approaches for treating CDI have been described, and this includes 
three broad approaches: antibiotic agents with higher specificity to C. difficile spare the 
normal microbiota
7
, biotherapeutic agents
8, 9, 10
, and vaccines
11, 12, 13
. In the case of 
vaccine development, the primary goal in the field has been to induce an anti-toxin 
immune response, as CDI is known to be a toxin-mediated disease. Some of these 
vaccines that target the toxins are currently undergoing clinical trials
12, 13
. However, an 
anti-toxin immune response is not likely to prevent colonization of patients with C. 
difficile, as many protected individuals that develop anti-toxin antibody responses can 
still shed spores into the environment and contaminate their surroundings. From an 
epidemiological standpoint, a vaccine that prevents colonization of patients and thus 
prevents the transmission of infective spores would be more ideal for containing the 
disease’s spread. Still, developing such a vaccine is a challenging process due to the 
complex nature of C. difficile colonization of the human host that is yet to be fully 
understood. Studies need to be conducted to identify target antigens and their ideal 
formulations in order to develop vaccines that prevent colonization. 
 This study aims to test the possibility of blocking C. difficile adherence to human 
gut epithelial cells, in order to identify candidate antigens and formulations for novel 
vaccine development that can prevent colonization. Bacterial adherence is thought to be 
an important part of colonization process. Thus, if a vaccine formulation could block 
adherence in an immunized host, it could prevent colonization. Antibodies against such 
antigen should block adherence of  the bacteria to gut epithelial cells in vitro. If not, a 
different formulation may be needed for effective vaccines. Three candidate molecules of 
C. difficile, HMW SLP, Cwp84, and FliD, are tested in this study to determine if 
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antibodies against these molecules can inhibit C. difficile adherence to Caco-2 BBE cells, 
a human colonic epithelial cell line.  
 
Clostridium difficile Infections 
 C. difficile, first identified in stool samples from infants and formerly known as 
Bacillus difficilis
14
, is a Gram positive anaerobe that is known to be one etiological agent 
of antibiotic-associated diarrhea (AAD)
15
. C. difficile produces two major toxins, toxin A 
(TcdA) and toxin B (TcdB), both of which are known to damage the gut mucosal barrier 
function through the disruption of the intracellular cytoskeletal network
16, 17
. The 
disruption of the gut mucosal barrier function leads to the recruitment of inflammatory 
cells to the site of damage and the patients subsequently suffer from diarrheal disease
18
.  
The traditional treatment for CDI, and the current one for mild cases, has been simply the 
stoppage of current antibiotic therapy until diarrhea resolves
6
. Unfortunately, the cases of 
CDI, based on hospital discharge diagnoses, increased in prevalence and also in disease 
severity between 1993 and 2005
19, 20
. Now, the rate of nosocomial (hospital-acquired) 
CDI has increased to the point that it rivals methicillin-resistant Staphylococcus aureus 
(MRSA)  infections
21
, and currently accounts for 20-30% of all cases of healthcare-
associated diarrhea
6
. 
 The explanation for the recent increase in the rate of CDI appears to be 
multifactorial. One major factor is the widespread use of antibiotics. It is known that use 
of antibiotics is a major risk factor for CDI
4
, supported by the fact that about 95% of the 
cases of CDI are healthcare-associated; patients who develop CDI typically have 
exposure to healthcare facility or service
5
. Another factor to be considered is the 
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emergence of hypervirulent strains of C. difficile. One prominent hypervirulent strain is 
known as BI, NAP1, or 027, depending on the method in which they were typed; there 
are other strains that are also considered hypervirulent but the BI group is the most 
common.  
 Compared to strain 630, the most well characterized strain of C. difficile to date, 
the hypervirulent BI strains are noted for their resistance to fluoroquinolones and a 
deletion in tcdC gene
22
; TcdC is thought to regulate the expression of tcdA and tcdB 
which code for the two major toxins of C. difficile
23
. The mechanism by which the 
change in TcdC expression in this strain contributes to hypervirulence is unclear
24 
as 
association of the mutation to actual disease severity has not been established
25
. Rather, 
factors contributing to the regulation of toxin production are very complex, as it has been 
demonstrated that toxin production is also linked to flagellar regulation
26, 27
 and response 
to environmental stress such as antibiotic exposure
28
. It is, however, clear that the 
severity and mortality rates of CDI have increased following the emergence of the 
hypervirulent strains, and many more cases today require measures beyond traditional 
methods to deal with CDI such as vancomycin
6
; in very severe cases, surgical removal of 
inflamed colon is performed. 
 A challenging issue that clinicians face today is recurrent CDI following 
treatment. Most CDI patients resolve their diarrhea and disease symptoms upon 
treatment.. However, after treatment is stopped, about 12-25% of patients experience 
disease relapse
3
; these recurring patients can experience multiple episodes of CDI, each 
after a course of CDI treatment. Repeated treatments and the added problem of serious 
complications requiring surgery have put a heavy financial burden on the healthcare 
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system, estimated to be $500 million annually in the United States
29
; another study 
estimates the cost to be over $3 billion
113
. Antibiotics are the treatment of choice when it 
comes to managing CDI. Currently, physicians try to manage disease recurrence with 
tapering antibiotic regimen, where the frequency of each antibiotic dosage is decreased 
over time
3
. However, antibiotics used for CDI treatment are also risk factors for CDI
4
, as 
they also disrupt the normal microbiota which prevents host colonization with C. difficile. 
 Animal models of CDI, traditionally using hamsters
30
 and more recently mice
31
, 
utilize antibiotic treatment followed by administration of infectious dose of C. difficile 
spores to induce disease. In these models, antibiotic administration is thought to disrupt 
the microbiota colonizing the intestine, leaving the animals permissive for C. difficile 
colonization. It has been demonstrated that a single dose of clindamycin, an antibiotic 
historically linked to CDI, causes significant alterations to the gut microbiota, leaving 
mice susceptible to CDI
32
. Likewise, another mouse model for CDI administers 
metronidazole and vancomycin to mice prior to C. difficile spore challenge
31
; these are 
the same drugs currently recommended for treatment of CDI patients. Thus, treatment of 
CDI puts some patients at increased risk for CDI, and when more contaminating C. 
difficile are ingested while at risk
33
 or persisting C. difficile grow, the patients can 
contract CDI again. This cycle of CDI recurrence is illustrated in Figure 1; patients 
undergo antibiotic therapy for CDI which can lead to subsequent CDI recurrence, and the 
disease cycle continues until successful therapy leads to a cure. To break such a 
destructive cycle, a novel approach to treating or preventing CDI is urgently needed. 
6 
 
 
 
Figure 1. Schematic diagram of CDI recurrence cycle. Antibiotic treatment leads to CDI 
which can be cured once antibiotic treatment is stopped. In some cases, CDI is treated 
using antibiotics. While this can cure CDI, it also puts one at risk for CDI. Thus, a 
destructive cycle of recurrent CDI can occur. ABX: antibiotics. Black Arrow: non-
recurrence disease pathway. Red Arrow: recurrent disease pathway. 
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Novel CDI Therapeutics 
 Looking at the rate of recurrent disease, and the financial burden it puts on the 
healthcare industry from repeated treatment regimen and severe complications, standard 
antibiotic therapy for CDI is becoming less effective. In response, there are many novel 
approaches to CDI treatment in development today. These new approaches can be 
classified into three groups: antimicrobial therapy, biotherapeutics, and immunologic 
therapy. 
 Currently, there are some novel antibiotic compounds tested to improve CDI 
treatment effects compared to vancomycin
34
. One of the novel antimicrobial therapeutic 
agents is called fidaxomicin, an antibiotic agent recently approved by the Food and Drug 
Administration (FDA) for the treatment of CDI. During clinical trials, this drug was 
shown to be equivalent to vancomycin, but a lower rate of recurrence was achieved 
compared to vancomycin in clinical trials
35
. A possible advantage of fidaxomicin is that, 
compared to standard antibiotics for CDI,  the drug is more specific for C. difficile; the 
microbiota isolated from stool samples from patients undergoing fidaxomicin therapy 
was altered to a lesser degree compared to samples from patients undergoing vancomycin 
therapy
36
. Fidaxomicin may lessen the risk for CDI recurrence by having a lesser impact 
on the microbiota compared to standard treatment options. This suggests that the increase 
in antibiotic specificity can lead to a better treatment for CDI that decreases the risk of 
recurrence. 
 Knowing about the importance of normal microbiota in CDI, treatment 
approaches using probiotics have been studied extensively. An alternative therapy that 
has shown success in treating CDI is fecal transplantation. This therapy seeks to restore 
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the balance in the microbiota of CDI patients, whose microbiota has been disrupted by 
antibiotic use and subsequent infection with C. difficile. The human gastrointestinal tract 
houses a large population of microbes consisting of fungi, viruses, archaea, small 
eukaryotes, and bacteria. These intestinal symbionts play a crucial role in the 
maintenance of human health, as the microbiota are involved in development and 
modulation of the host immune system
37, 38, 39, 40
, host metabolic processes
41
, and 
protection from pathogens
42, 43
. In the case of CDI, the normal microbiota seems to confer 
colonization resistance against C. difficile, as antibiotic administration alters the 
microbiota to confer susceptibility to CDI
32
. Fecal transplantation transfers microbiota 
from a healthy donor to a CDI patient whose microbiota is altered, and thus colonization 
resistance is established in the CDI patient. This therapy has shown success, including a 
recent clinical trial showed greater success with fecal transplants when compared to 
standard vancomycin therapy in curing CDI and in limiting recurrence
10
. While the 
therapy is effective, the specific effector organisms in fecal transplantation involved in 
protection from CDI have not been identified, not to mention that many have never been 
successfully cultured for study before. As studies continue, the microbes needed to 
induce colonization resistance against C. difficile will be identified and lead to specific 
probiotic therapeutics in the near future. 
 Immunologic therapy for CDI has been under study for more than twenty years
44
; 
a vaccine for CDI was studied in hamsters using formalin-inactivated C. difficile cells and 
culture filtrates in 1995
45
. Since CDI is mediated by the two major toxins, vaccines 
targeting these toxins as antigens remain the best studied so far. The development of anti-
toxin antibody response is suggested to be protective against disease symptoms, since 
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asymptomatic carriers have increased levels of anti-TcdA IgG serum antibodies 
compared to symptomatic patients
46
. Also, human monoclonal antibodies (mAb) against 
toxins have been shown to protect hamsters from lethal C. difficile challenge
47
, and to 
reduce the rate CDI recurrence among patients given toxin-specific mAb
48
. The most 
promising vaccine target currently seems to be a fusion protein of TcdA and TcdB 
receptor binding domains
 
that was shown to be effective in a mouse model
49
; targeting 
both toxins is preferred because the relative importance of TcdA versus TcdB in disease 
is not entirely clear (strains expressing either both toxins or TcdB only can all cause 
disease). Meanwhile, it has been shown that a toxin B targeting vaccine does not prevent 
C. difficile colonization in hamsters while it does protect the animals from disease when 
challenged with a strain only producing TcdB
11
. Because toxins are not assumed to be 
involved in the initial colonization process, vaccines targeting the toxins would not likely 
prevent colonization in patients whose intestinal microbiota is disrupted. Thus, a 
successful toxin-based CDI vaccine may result in asymptomatic carriage and subsequent 
spread of infectious spores to the environment including hospital surfaces. In order to 
design a vaccine that prevents colonization and subsequent CDI, this study aims to test 
candidate adhesins of C. difficile to determine if antibodies against chosen molecules 
could block adherence. Such a vaccine, by preventing adherence and subsequently 
colonization, could prevent disease and its spread. 
10 
 
Therapy Examples Potential Cost 
Microbiota-
sparing ABX 
Fidaxomicin High 
Biotherapeutics 
B. coagulans, Lactobacilli, Fecal 
transplantation, Non-toxigenic C. 
difficile 
Low 
Immunologics 
mAb High 
Vaccines Likely low 
 
Table 1. Summary of developing therapeutics for CDI and potential cost estimate of each 
category.
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Candidate Molecules for Vaccine Development 
 Bacterial flagella are recognized to be virulence factors in many different 
pathogens, serving a variety of functions including role in motility
50
. In particular, FliD, 
the capping protein for the flagellar apparatus in many bacteria, has been demonstrated to 
play a role in colonization of mammalian hosts in different bacteria
51, 52
. In the case of C. 
difficile, FliC is the flagellin subunit that makes up the fibrous portion of the flagella, 
while FliD serves as the capping protein at the outer tip of the flagellar structure, as 
illustrated in Figure 2. Both FliC and FliD have been shown to bind to mucin, a protein 
component of intestinal mucus, and FliD has also been found to bind to epithelial cells in 
vitro
53
. The in vivo significance of FliD in colonization and disease is not clear, as studies 
with a mutant unable to produce FliD found the mutant to have enhanced virulence
26
; this 
is inconsistent with the previous finding that flagellated strains tend to have increased 
adherence compared to non-flagellated strains within the same serogroup
53
. However, 
this increase in virulence may be a byproduct of mutagenesis itself, as toxin production 
was found to be increased in fliD mutants
26
; the regulation of toxin production was found 
to be partly related to flagellar regulation
27
. While both FliC and FliD seem to be 
involved in the colonization process, it was shown that CDI patients tend to generate 
more antibodies against FliD than FliC
54
. FliC has been shown to have variability in 
DNA restriction fragment length polymorphism (RFLP) patterns and in protein sequence 
amongst different serogroups of C. difficile
55
, meaning there is limited antibody cross-
reactivity for FliC among C. difficile strains. In contrast, antibodies produced against 
FliD of one serotype cross-reacts with FliD from other serotypes
56
. This can make FliD a 
12 
 
good vaccination target as the immune response generated by this molecule likely will be 
directed against multiple strains and thus confer protection against multiple strains.
13 
 
 
 
Figure 2. Illustration of C. difficile cell with a flagellar structure. FliC is the flagellin 
subunit while FliD is the capping protein. The flagellar fiber is attached to a flagellar base 
apparatus on the cell. C. difficile is known to express multiple flagellar fibers, but only 
one is illustrated in this figure.
14 
 
 C. difficile, like many other bacteria, has a protein array that covers the surface of 
the cell in close association with its cell surface
57
. The proteins, termed surface layer 
proteins (SLPs), serve a variety of functions including protective coating, adhesion, ion 
trapping, cell shaping, and cell division in a variety of different organisms of both 
bacteria and archaea
58
. Although the sequence and structure of SLPs are very diverse 
amongst different species, SLPs have co-evolved to share some properties such as self-
assembly, regularity of pores, and association with the underlying cell surface structure
58
. 
In C. difficile, the SLP monomers are made of two subunits of different size, termed low-
molecular weight (LMW) and high-molecular weight (HMW) SLP
57
. These proteins are 
encoded by slpA gene which translates into a precursor protein that is cleaved by 
proteolysis into the two subunits
59
. The subunits then form a stable complex that serves 
as the monomer to subsequent S-layer self-assembly as illustrated in Figure 3
60
. One 
suggested function of the SLPs in C. difficile is adhesion to host intestinal mucosa, as the 
proteins were found to be associated with colonic sections of both humans and mice upon 
co-incubation with tissue samples; SLPs were also shown to interfere with C. difficile 
adhesion to HEp-2 cells
61
, an epithelial cell line derived from HeLa cell contaminants
62
. 
Thus, SLPs seem to be a good target for vaccine development since they are associated 
with adhesion process and covers the entire cell surface. Also, the proteins form an array 
of identical subunits, which likely makes them good immunogens. The structural studies 
indicate that LMW SLP is more surface exposed
60
 and likely more immunodominant. 
However, LMW SLP shows high antigenic diversity among the different strains of C. 
difficile and such, a vaccine may confer protection against only a few strains
59
.  
15 
 
 
Figure 3. Illustration of C. difficile cell wall structure with overlaying S-layer. A. The 
plasma membrane is covered with a thick peptidoglycan layer characteristic of a Gram 
positive organism. The SLP paracrystalline layer is closely associated with the 
peptidoglycan layer through conserved domains in HMW SLP. Other cell wall proteins 
are incorporated into the S-layer. B. Illustration of the SlpA, the precursor molecule for 
the SLPs. The triangles denote proteolytic cleavage sites in the maturation process. SlpA 
does contain a signal peptide (left-most portion of SlpA in B) believed to be involved in 
the secretion pathway for the molecule. Figure from Fagan et al. 2009. Molecular 
Microbiology
60
. 
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 In contrast, HMW SLP is less exposed to the host immune system to recognize 
and is thought to be localized more towards the interior part of the S-layer due to its 
interactions with the underlying cell wall
60
. Despite the localization, HMW SLP was 
found to be an immunoreactive cell wall protein in sera of CDI patients
63
, indicating that 
the antigen can be exposed to the host immune system. The HMW SLP is more 
conserved amongst different strains of C. difficile, since it must have domains that 
interact with the Gram positive peptidoglycan layer. Indeed, antibodies raised against 
HMW SLP of strain 630 cross-reacts with HMW SLP of other strains including toxigenic 
and non-toxigenic strains
59
. Thus, in contrast to LMW SLP, a vaccine targeting HMW 
SLP could confer protection from many different strains of C. difficile. 
 As illustrated in Figure 3, the S-layer of C. difficile does contain various other 
molecules. Many of these proteins are paralogs of SlpA called cell wall proteins (Cwp), 
as they share three putative cell wall binding repeat 2 (Pfam 04122) domains to interact 
with the underlying cell wall
64
. Each paralog has its own unique domain that may provide 
a variety of different functions
65
. One particular Cwp of interest is Cwp84, a cysteine 
protease known to be responsible for the proteolytic cleavage of SlpA into the LMW and 
HMW SLP subunits
66, 67
. This processing of SlpA is critical for the generation of a proper 
S-layer, since insertional disruption of cwp84 gene expression results in cell wall proteins 
and SlpA being found in the culture supernatant, indicating poor incorporation of the 
proteins into the S-layer
68, 69
. Multiple forms of Cwp84 are known to exist during its 
maturation process, but which form or forms, under in vivo conditions, cleaves SlpA is 
not yet clear
69
. Other than the cleavage of SlpA, Cwp84 protease function extends to 
many other targets including host extracellular matrix proteins
70
. Precisely what the in 
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vivo role of degrading extracellular matrix proteins serves for C. difficile pathogenesis is 
unclear. While the question of whether an antibody response directed against Cwp84 is 
protective is unknown for humans, some patients do make antibodies against Cwp84
63
, 
and Cwp84 has been tested in active immunization of mice for protection along with 
FliD
71,72
. Perhaps an antibody response could interfere with the incorporation of Cwp84 
into the S-layer during its assembly or affect the protein in a way the function can be 
blocked. This study is designed to test whether antibodies against Cwp84 could alter C. 
difficile adherence in vitro. 
 
Other Virulence Factors 
 Studies of C. difficile adhesion interference in the literature have always reported 
partial decreases in adherence
61, 73
, and vaccination studies of animals, while they have 
suggested protection, have not demonstrated complete clearance of pathogen from the 
animal
71, 74
. This suggests that C. difficile utilizes many different molecules and pathways 
in its colonization process of the host. Studies of C. difficile proteins have been difficult 
due to the lack of genetic tools to generate mutants. However, a new system utilizing 
homologous insertion with bacterial conjugation, named ClosTron
75
, has allowed for the 
generation of functional knockouts in C. difficile and study of specific molecules became 
more available. Many different factors for colonization in addition to the ones listed in 
the previous section have been previously described, and many hold therapeutic potential 
for CDI. 
 One of the earliest discovered adhesin for C. difficile was Cwp66, a SlpA paralog 
like Cwp84. The study of Cwp66 revealed that antibodies against Cwp66 inhibited C. 
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difficile adhesion to Vero cells, a monkey kidney epithelial cell line
76
. An interesting 
aspect of Cwp66 is that it is not present at the cell surface under normal culture 
conditions, but upon heat-shock at 60°C for twenty minutes, Cwp66 localizes to the cell 
surface, perhaps to the S-layer since the protein is a SlpA paralog. Also, the antibody-
mediated adhesion interference with Cwp66 was limited to the heat-shocked C. difficile 
with antibodies against Cwp66 from heat-shocked bacteria
76
. It was subsequently found 
that Cwp66 has distinct antigenic properties after heat-shock, as antibodies against 
normal Cwp66 did not recognize the heat-shock induced Cwp66 and vice versa
76
. Thus, it 
is not clear yet how Cwp66 actually may mediate adhesion in vivo, and the question of 
Cwp66 as a potential vaccine antigen remains open. 
 Another heat-shock protein identified to have a role in C. difficile adhesion is 
GroEL (or heat-shock protein 60, Hsp60). In heat-shocked C. difficile, GroEL was found 
to be localized to the cell surface and recombinant GroEL or antibodies against GroEL 
both inhibited adherence of heat-shocked C. difficile
77
. However, GroEL lacks the signal 
peptide normally present in bacterial molecules that localize to the cell surface, so how 
GroEL may be exposed to antibodies in this case is unclear. Seeing that many 
environmental stress factors such as high acidity, high osmolarity, iron deficiency, and 
heat stress modulate adherence in C. difficile
78
, that transcription of genes from the 
pathogenicity locus that codes for TcdA and TcdB increases during later phases of 
growth in culture when nutrients are relatively scarce
79
, and that many other virulence 
genes are upregulated under stress conditions like high salt concentration and 
subinhibitory antibiotic dose in culture
80
, there may be an association between C. difficile  
virulence and environmental stress the bacteria face. Although it is unknown if an 
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immune response against stress-induced molecules including GroEL would be able to 
protect from CDI since the expression profile of these molecules is unknown in in vivo 
conditions, it may still be a feasible approach to target stress-related molecules for 
vaccine development to prevent C. difficile colonization.  
 It has been thought that C. difficile adheres to the brush border components of the 
intestine since the bacteria were observed to be associated with the apical tip of the brush 
borders of Caco-2 cells, a human intestinal cell line derived from a colon carcinoma. Also, 
it was also shown that the increase in brush borders, through spontaneous differentiation 
of Caco-2 cells in culture, seemed to increase the level of adherencce
81
. However, it was 
demonstrated that treatment of Caco-2 cells with calcium ion (Ca
2+
) chelators such as 
ethylene glycol tetraacetic acid (EGTA) to expose the basolateral side of the Caco-2 
through the disruption of the intercellular junctions increases adherence of C. difficile, 
and that C. difficile seems to associate with projections that look like extracellular matrix 
(ECM) components when observed by scanning electron microscopy (SEM); it was 
confirmed that the bacteria can bind to immobilized ECM proteins
82
, suggesting that C. 
difficile can bind to ECM proteins for adherence to Caco-2 cells. 
 Fibronectin is a ubiquitous protein of about 440kD that is a major part of the 
ECM that supports various tissues
83
. It is known that Streptococcus pneumoniae (S. 
pneumoniae) and Streptococcus pyogenes (S. pyogenes) bind to fibronectin
84, 85
, and that 
this process seems to be mediated by fibronectin-binding proteins (Fbp)
86
. C. difficile also 
possesses FbpA (noted FbpA in strain 630 and Fbp68 in strain 79-685) that mediates C. 
difficile binding to immobilized fibronectin
87 
in manganese (Mn
2+
) dependent manner
88
. 
Although anti-Fbp68 antibodies showed interference of C. difficile adherence to Vero 
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cells
87
, suggesting that Fbp68 may mediate adherence to epithelial cells, disruption 
mutants of fbpA (ΔfbpA) showed increase in adherence to Caco-2 and HT29-MTX 
(mucus producing human intestinal epithelial cell line)
89
, suggesting that the role FbpA 
plays in overall C. difficile adherence remains to be understood. Still, the same study 
demonstrated that the ΔfbpA mutant poorly colonized mice in two of three models of 
differing intestinal microbiota compared to wild-type C. difficile
89
, and the bacteria 
possesses Cwp84 which can exert proteolytic functions against ECM proteins
70
, 
suggesting that C. difficile interaction with ECM proteins like fibronectin may still be 
important in the overall colonization process. 
 The emergence of hypervirulent strains of C. difficile has compounded the 
challenge for clinicians to treat CDI. One feature of the BI group (by restriction 
endonuclease analysis (REA) typing and 027 by polymerase chain reaction (PCR) 
ribotyping), one of the hypervirulent strains, is the production of binary toxin (CDT) in 
addition to TcdA and TcdB. CDT is an actin-specific adenine diphosphate (ADP)-
ribosyltransferase that has cytotoxic effects in Vero cells that can be neutralized by 
antibodies against Clostridium perfringens (C. perfringens) iota toxin
90
. CDT is a 
member of iota-family binary toxins present among many different species of 
Clostridia
91
. The iota family binary toxin functions are known to be mediated in part by 
CD44 on host cell surface that serve a variety of functions in different cells
92
, as CD44
-/-
 
cells are known to be resistant to the cytotoxic effects of these toxins
93
. Also, lipolysis-
stimulated lipoprotein receptors (LSR) seem to be important for CDT uptake since CDT 
can induce clustering of LSRs into lipid rafts
94
, a possible mechanism for subsequent 
signaling. Other than cytotoxic effects in some cell lines, an interesting function that 
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CDT has is the effect on microtubular network in Caco-2 cells, where the treatment of 
Caco-2 cells with CDT induced microtubule-based thin projections from the host cell 
surface that formed a net that seemed to trap C. difficile, and this indeed correlated with 
increased adhesion; this process was demonstrated to also be neutralized by treatment 
with anti-iota toxin antibodies
95
. While it can be assumed that the production  of binary 
toxin by the hypervirulent strains could help the C. difficile to adhere better to intestinal 
epithelium via this microtubule extension mechanism, further studies are needed to see if 
the production of binary toxin indeed contributes to colonization and subsequent disease. 
 
Biofilms and Spores  
 Many bacteria form a biofilm, a complex structure consisting of specialized 
microbial communities, polysaccharides, and other compounds
96
. These community 
structures can form on many different surfaces including biological surfaces like the 
gastrointestinal epithelium. Biofilms provide the microbial community many 
characteristics such as resistance to antimicrobial compounds and resistance to sheer 
forces
96
. It is thought that a freely moving, planktonic bacterium comes in contact with a 
surface to which the bacterium first associates with then adheres to. At certain point, the 
bacteria start to produce extracellular material in which the colony becomes encased. 
Subsequently, signals are produced to differentiate cells within the biofilm structure and 
more matrix components are produced. Fragments of biofilm can become detached from 
the biofilm structure and cells are dispersed. The general process of bacterial biofilm 
development is illustrated in Figure 4. 
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Figure 4. Illustration of bacterial biofilm formation. A. Free-swimming, planktonic 
bacterium comes in contact with intestinal epithelial surface. Adherence to surface 
usually induces downregulation of mobility-associated gene expression. B. Adherence 
bacteria grow and form a colony. Colony starts to produce extracellular components. C. 
Community of bacteria is now encased in thick extracellular matrix which serves a 
variety of functions including resistance to antimicrobial compounds. D. Certain factors, 
such as strong sheer forces can induce dispersal of new planktonic bacteria or even a part 
of biofilm matrix containing matrix components and bacterial cells to be released to 
spread elsewhere. Based on Hall-Stoodley et al. 2004. Nature Reviews Microbiology.
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 C. difficile has also been demonstrated to form biofilms, especially when co-
cultured with certain bacteria
97
. It was also determined that biofilm formation by C. 
difficile in vitro requires cwp84, spo0A, and luxS gene expression since the insertional 
disruption mutants of each gene did not form biofilms
98
. This suggests that proper S-layer 
processing, sporulation, and quorum sensing are required for biofilm formation, 
respectively. It is interesting to note that spo0A, whose protein product Spo0A is known 
to be the master regulator of sporulation that determines cell fate to become a spore in 
Bacillus subtilis (B. subtilis)
99
 and C. difficile
100
, is required for biofilm formation. The 
authors of the C. difficile Spo0A study also found that defect in sporulation increases 
TcdA and TcdB, increases virulence in the hypervirulent strain in mice, and decreases 
transmission of CDI to other mice as fecal shedding was eliminated. This is interesting 
because one speculated mechanism in which recurrence can occur is through persistence 
of C. difficile in the patient gastrointestinal (GI) tract which may be mediated in part by 
resistant biofilm formation. The persisting C. difficile could then grow again while the 
intestinal microbiota is still depleted following antibiotic treatment for CDI. If 
sporulation is indeed a critical process for biofilm formation in vivo as suggested by in 
vitro experiments, perhaps sporulation could be a target for novel therapeutics that could 
alleviate disease recurrence. However, the degree to which biofilm formation actually 
contributes to in vivo colonization is unknown, and further studies need to be done to 
confirm that biofilm can be a target for preventive therapeutics for CDI.  
 Bacterial spores are a dormant form of the organism designed for prolonged 
survival and resistance to a variety of environmental stresses. Thus, C. difficile is not 
metabolically active and does not produce toxins while in the spore form; for CDI to 
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occur, the spores must germinate and form vegetative cells. C. difficile spores are known 
to adhere to surfaces such as semi-solid agar surface
2
 and the intestinal cell line Caco-2
101
. 
While it may be that the spores of C. difficile likely can adhere to GI epithelium, the 
extent to which such process contributes to overall colonization of the host is unknown. If 
spores contribute in part to adherence and persistence of the organism in the host, 
vaccines targeting spores or spore components may be a possible way to prevent CDI and 
its recurrence. 
 There is an interesting surface protein on C. difficile S-layer known as CwpV. 
CwpV is also a paralog of SlpA that contains a repeat domain unique to CwpV; this 
domain seems to have antigenic variability amongst different strains
102
. Like many of the 
SlpA paralogs, CwpV also undergoes maturation process through proteolytic cleavage, in 
this case by autoproteolysis
103
. While variable amongst different strains, this protein does 
seem to have a conserved function in promoting bacterial self-aggregation
102
. While the 
in vivo significance of this function is still unknown, it can be speculated that this 
function may be important in biofilm formation; it has been demonstrated in other 
bacteria that autoaggregation seems to contribute to initial stages of biofilm formation
104
. 
Interestingly, CwpV is known to be regulated at the transcriptional level by DNA 
inversion mediated by specific recombinases, allowing for phase-variable expression
105
. 
Although the expression of CwpV under in vivo settings is unknown, CwpV was 
demonstrated to be the major Cwp within the S-layer when its recombinational 
transcription switch is turned on
102
. Perhaps when the conditions are set for biofilm 
formation, CwpV may be expressed within the S-layer to promote self-aggregation which 
then may contribute towards biofilm formation. An antibody response that blocks this 
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autoaggregation function may affect biofilm formation. However, more studies are 
needed to evaluate this possibility. 
 There are many molecules of C. difficile that have been identified to potentially 
play a role in colonization of the host along with a variety of mechanisms of colonization. 
Many of these molecules possess the potential for being targeted by vaccines to induce 
protection in human hosts from CDI. The molecules described in this document are listed 
in Table 2. In addition, there are certainly other molecules and mechanisms contributing 
to host colonization and disease yet to be identified. Thus, the potential for developing 
and improving a vaccine that could prevent CDI is vast. 
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Virulence 
Factor 
Description Possible contribution to CDI 
TcdA/B Major toxins Disruption of host epithelium 
FliC Flagellin subunit Mucin binding 
FliD Flagellar cap Mucin/Epithelial binding 
SlpA S-layer protein 
Molecular exclusion, host 
epithelial binding 
Cwp84 Cysteine protease SlpA processing 
Cwp13 Cysteine protease 
SlpA processing, Cwp84 
processing 
Cwp66 Heat-shock adhesin 
Adhesion to epithelium under 
heat-shock 
GroEL Heat-shock protein 
Protein refolding, adhesion 
under heat-shock 
FpbA/68 
Fibronectin binding 
protein 
ECM binding 
CbpA
106
 
Collagen binding 
protein 
ECM binding 
CdtA/B Binary toxin 
Cytotoxicity, microtubular 
trapping of bacteria for 
enhanced adhesion 
Spo0A 
Master regulator of 
sporulation 
Sporulation, biofilm formation 
CwpV Autoaggregation protein Biofilm formation? 
 
Table 2. List of C. difficile virulence factors, description of their function, and potential 
contributions to disease. 
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Mucosal Vaccines Targeting Colonization 
 The mucosal layer serves as the interface in which host and microbes interact, and 
thus the host immune system is highly active at mucosal surfaces. A major component of 
the mucosal immune system is secretory immunoglobulin A (sIgA). In the mucosa, sIgA 
serves a variety of functions including prevention of bacteria adhesion
107
. As many 
infectious agents initiate pathogenesis at this mucosal interface, developing a mucosal 
immune response such as sIgA can prevent pathogenic processes from initiating and thus 
protect the host from disease. However, the mechanism by which the sIgA (dimeric form 
of IgA) response is generated is separate from the systemic antibody response that is 
primarily IgG and monomeric IgA. As the transcytosis of immunoglobulins into the 
mucosal layer is mediated by polymeric Ig receptor (pIgR), systemic antibodies generated 
through systemic vaccine administration are thought not to cross into the mucosal surface. 
In contrast, a mucosal vaccine would induce specific responses targeting to the mucosa 
that would cross into the mucosal layer and function against mucosal pathogens. In 
targeting microbial factors for colonization, such a mucosal response may prevent host 
colonization with the target pathogen. 
  There are many vaccines that are designed to induce a mucosal immune response, 
including vaccines for cholera, typhoid fever, rotavirus, influenza, and polio
108
. One 
interesting vaccine in current use is the heptavalent pneumococcal conjugate vaccine 
(PCV7). This vaccine consists of surface carbohydrates from different serotypes of 
Streptococcus pneumoniae (S. pneumoniae) conjugated to diphtheria toxin. While this 
vaccine is delivered systemically and not by a mucosal route, it was demonstrated that in 
children vaccinated with PCV7, the S. pneumoniae colonizing the nasopharyngeal 
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mucosa becomes seroconverted, where the strains of bacteria colonizing the vaccinated 
children converts to non-vaccine strains
109
. This suggests that vaccination prevents 
children from being colonized with vaccine-targeted strains S. pneumoniae. In the case of 
C. difficile, toxin-targeting vaccines have been the focus of research, whereas studies to 
develop vaccines that could prevent colonization have been few. One study measured the 
level of C. difficile recovery from feces after challenging mice with or without 
immunization with FliD, Cwp84, cell wall extract, flagellar preparation, or a combination 
through various mucosal routes
71
. While the study demonstrated a slight decrease in C. 
difficile recovery in immunized mice, the vaccine failed to prevent colonization. This 
may have to do with the efficacy of the vaccination itself, since only the rectal 
administration resulted in the production of antigen-specific IgA in the intestinal lavages 
of mice while other routes had resulted in almost undetectable IgA levels. With the 
uncertainty about the mechanisms behind C. difficile adhesion and colonization process, 
further studies are still needed to develop a vaccine that can prevent colonization. 
However, other mucosal vaccines already licensed for clinical use, and the success that 
some vaccines have had in preventing colonization, suggest that prevention of CDI by 
targeting colonization is possible. 
 
Caco-2 BBE Colon Adenocarcinoma Cell Line 
 In order to test antibodies for their ability to interfere with C. difficile adherence, a 
system modeling the gut epithelial surface has to be established. The Caco-2 cell line is 
derived from human colon adenocarcinoma and is able to spontaneously differentiate and 
polarize to have enterocyte-like qualities such as brush borders. Caco-2 brush border 
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expressing clone (BBE) cells, derived from Caco-2 cells
110
, have been chosen as the 
model for gut epithelial surface in this study. In the past, Caco-2 cell line has been used 
in bacterial adherence assays under anaerobic conditions, which is crucial for the growth 
and survival of vegetative cells of C. difficile. The Caco-2 survival was reported to be 98% 
after three hours of incubation under anaerobic conditions
111
. Studies involving adhesion 
interference in C. difficile have utilized mainly Vero cells
53
 and Hep-2 cells
61
, which can 
bind enteric pathogens but are not of colonic origin. Thus, the Caco-2 BBE cell line has 
been chosen since the cells are of colonic origin and express brush borders which C. 
difficile has been suggested to associate with
81
. 
 
Experimental Design 
 In order to test antibodies targeting certain molecules of C. difficile in their ability 
to interfere with adherence, target molecules, FliD, HMW SLP, and Cwp84 will be 
produced as recombinant proteins from Escherichia coli (E. coli). The recombinant 
proteins will be used as immunogens for antibody production in rabbits. Adhesion levels 
to Caco-2 BBE cells will be compared between C. difficile pre-treated with pre-immune 
serum and serum specific for the target molecules. If the molecules are indeed involved 
in C. difficile adhesion to Caco-2 BBE cells, the antibodies should reduce the number of 
adherent bacteria compared to naïve serum. 
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CHAPTER TWO 
MATERIALS AND METHODS 
C. difficile Culture 
 C. difficile strain 630 spores were streaked onto 10% sheep blood agar plates 
(BAP) (BD Bioscience, Franklin Lakes, New Jersey) and incubated for 48 hours at 36°C 
under anaerobic conditions (80% N2, 15% CO2, and 5% H2) in a Bactron IV anaerobic 
chamber (Shel Lab, Cornelius, Oregon). A single colony of C. difficile was inoculated 
into 20mL anaerobic tryptic soy broth (TSB) (BD Bioscience) and grown overnight (16-
18 hours) at 36°C anaerobically. Alternatively, a C. difficile colony was inoculated into 
brain-heart infusion broth (BHI) (BD Bioscience) and grown overnight. 
 
Isolation of C. difficile Genomic DNA 
 An overnight culture of C. difficile 630 was prepared in TSB, and the cells were 
pelleted by centrifugation at 3,000xG for 10 minutes at 4°C using Allegra
TM
 6R 
centrifuge (Beckman-Coulter, Fullerton, California). Cells were resuspended in 3mL 
50mM EDTA solution. Lysozyme, mutanolysin, and lysostaphin were added to 15mg/mL, 
1U/mL, and 500μg/mL respectively into the resuspension. RNase A was added to active 
concentration of 200μg/mL and the mixture was incubated at 37°C for 1 hour. Proteinase 
K and SDS was added to 2.25mg/mL and 1.8% (w/v) respectively, and the mixture was 
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incubated at 50°C for another 1 hour. Phenol:chloroform:isoamyl alcohol (3mL) was 
added to the mixture, and the mixture was centrifuged at 1,500xG for 5 minutes. The 
upper phase was taken and the DNA was precipitated by adding 8mL 100% ethanol and 
incubating overnight at -20°C. DNA was pelleted by centrifugation at 3,000xG for 30 
minutes at 4°C and the pellet was resuspended in 100μL TE buffer after washing and air-
drying. Genomic DNA was stored at 4°C until use. 
 
PCR Amplification of Target Genes 
 Target coding regions of genes fliD, slpA, and cwp84 were amplified by PCR with 
Phusion high-fidelity DNA polymerase (Thermo Scientific, Pittsburg, Pennsylvania) 
using specific primers as listed in Table 3. Primers were designed to incorporate BamHI 
and XhoI restriction sites to the PCR products. PCR products were separated by 1% 
agarose gel electrophoresis and bands corresponding to target size were cut out and 
eluted from gel using Wizard
®  
PCR Preps DNA Purification System (Promega, Madison, 
Wisconsin). PCR product was then ligated into pGEM
®
-T Easy vector (Promega) and 
subsequently transformed into E. coli DH10B by electroporation using Gibco-BRL Cell-
Porator (Life Technologies, Grand Island, New York). Transformed cells were selected 
for resistance against 100μg/mL ampicillin and by blue-white colony screening on Luria-
Bertani (LB) (BD Bioscience) agar plates overnight at 37°C. Selected clones were 
cultured overnight at 37°C in LB broth then stored at -80°C as 20% glycerol stocks. 
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Name Gene Orientation Sequence 
Tm 
(°C) 
Notes 
fliD 
FWD 
fliD Forward 
5'-ATCG GGA TCC 
ATG TCA AGT ATA 
AGT CCA GTA AG-3' 
60.2 
Entire coding region 
fliD 
REV 
fliD Reverse 
5'-ATCG CTC GAG 
ATT ACC TTG TGC 
TTG TGA GA-3' 
62.4 
slpA 
FWD 
slpA Forward 
5'-TAAG GGA TCC 
GCA AAT GAT ACA 
A-3' 
54.2 
HMW SLP coding 
region 
slpA 
REV 
slpA Reverse 
5'-AGG CTC GAG 
CAT ATC TAA TAA 
A-3' 
51.0 
cwp84 
FWD 
cwp84 Forward 
5'-TGA GGA TCC 
GCA GAA AAC CAT 
AAA ACT CTA GAT 
G-3' 
60.8 
Mature form coding 
region 
cwp84 
REV 
cwp84 Reverse 
5'-CCG CTC GAG 
AAC TGC TGT TTC 
ATA TC-3' 
59.4 
 
Table 3. List of primers used in the study. The incorporated restriction site sequences are 
noted in bold. The entire fliD coding region was amplified, compared to slpA and cwp84 
where only a part of the coding region of interest was amplified. All primers were 
ordered from Integrated DNA Technologies (Coralville, Iowa). Bold text indicates the 
BamHI and XhoI restriction sites. 
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Construction of Expression Plasmids 
 E. coli clones harboring pGEM
®
-T Easy constructs with target gene inserts were 
streaked onto LB agar plates containing 100μg/mL ampicillin and incubated overnight at 
37°C. Single colonies were inoculated into LB broth with 100μg/mL ampicillin for 
overnight culture at 37°C. Plasmid DNA from the overnight culture was isolated using 
the Wizard
®  
Plus SV Minipreps DNA Purification System (Promega). DNA was stored at 
-20°C. pGEM
®
-T Easy constructs were digested with BamHI and XhoI for 1 hour at 
37°C, and pET-21a(+) vector (Merck KGaA, Darmstadt, Germany) was also digested 
with BamHI and XhoI for 1 hour. The pET-21a(+) vector was treated with shrimp 
alkaline phosphatase (SAP) for 30 minutes at 37°C. Resulting DNA fragments were 
separated by 1% agarose gel electrophoresis and bands corresponding to target genes and 
pET-21a(+) were cut out, eluted from gel, then subsequently ligated to generate the 
expression plasmid constructs. The expression plasmid constructs were transformed into 
E. coli DH10B cells by electroporation and colonies were selected by 100μg/mL 
ampicillin on LB agar plates after overnight culture at 37°C. Plasmids were extracted 
from overnight LB broth culture and digested for 1 hour with BamHI and XhoI at 37°C. 
The products were analyzed by 1% agarose gel electrophoresis to confirm the presence of 
correct plasmid and insert. Clones harboring correct plasmid construct were cultured 
overnight in LB broth and stored at -80°C as 20% glycerol stocks. A list of plasmid 
constructs and the parent plasmids can be found in Table 4. All plasmid constructs, 
including pGEM
®
-T Easy and pET-21a(+) constructs were sequenced using ABI Prism 
3130 Genetic Analyzer (Life Technologies) to confirm that the cloning was successfully 
done in frame. For sequencing, lowered extension temperature (50°C for 4 minutes) was 
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used due to the high AT content of target genes, as it has been demonstrated that lowered 
extension temperatures in PCR enhances amplification in AT-rich templates
112
. For 
pGEM
®
-T Easy constructs, T7 promoter-specific and SP6 promoter-specific primers 
were used while for pET-21a(+) constructs, the T7 promoter-specific and T7 terminator-
specific primers were used, all ordered from Integrated DNA Technologies. 
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Plasmid Description Marker 
pGEM
®
-T Easy 
Plasmid for cloning PCR products, 
contains hanging T edges 
Ampicillin, 
Blue-white 
pGEM
®
-T 
Easy-fliD 
fliD cloning plasmid construct 
pGEM
®
-T 
Easy-slpA 
slpA cloning plasmid construct 
pGEM
®
-T 
Easy-cwp84 
cwp84 cloning plasmid construct 
pET-21a(+) Parent plasmid for expression 
Ampicillin 
pET-21a(+)-
fliD 
fliD expression plasmid construct 
pET-21a(+)-
slpA 
slpA expression plasmid construct 
pET-21a(+)-
cwp84 
cwp84 expression plasmid construct 
pRARE2 
Encodes tRNA genes rare in E. coli to 
address codon bias 
Chloramphenicol 
 
Table 4. List of plasmids used in this study. The pRARE2 plasmid is already contained 
by the E. coli Rosetta 2 (DE3) cells by design (Merck KGaA). 
  
36 
 
 
Expression of Target Proteins 
 The pET-21a(+) expression plasmid constructs were transformed into E. coli 
Rosetta
TM
 2 (DE3) cells (Merck KGaA) by electroporation. The Rosetta
TM
 2 strain of E. 
coli contains pRARE2, which is a plasmid encoding tRNA genes rare in abundance in E. 
coli. This addresses codon bias in E. coli that limits the proteins bacteria can express, and 
allows for genes from C. difficile, whose proteins utilize some of these rare codons, to be 
expressed more proficiently. The transformed cells were selected with 34μg/mL 
chloramphenicol and 200μg/mL ampicillin on LB agar plates. Clones harboring the 
plasmid constructs were screened by colony PCR using primers specific for each target 
insert (listed in Table 4). Briefly, the PCR template was prepared by picking a single 
colony into 100μL dH2O and heating at 100°C for 90 seconds. This sample (1μL) was 
used as the template for colony PCR using the Phusion DNA polymerase.  PCR products 
were analyzed by 1% agarose gel electrophoresis. Clones confirmed to harbor correct 
plasmid construct were stored at -80°C as 8% glycerol stocks. 
 Expression clones were cultured overnight in LB broth containing 34μg/mL 
chloramphenicol and 200μg/mL ampicillin. The overnight culture was diluted into fresh 
LB broth 1:50 and cultured until OD600nm reached 0.5. At this point, IPTG was added to 
0.5mM to induce protein expression for 3 additional hours. Cells were harvested by 
centrifugation at 3,000xG for 5 minutes at 4°C, and resuspended in 1mL of 50mM 
NaH2PO4, 300mM NaCl solution. Lysozyme was added to 100μg/mL and the mixture 
was stored at -80°C to facilitate lysis by freeze-thaw cycles. Thawed lysate was 
subsequently cleared by sonication and the soluble and insoluble molecules were 
separated by centrifugation at 14,000xG for 15 minutes at 4°C using Sorvall Legend 
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Micro 21R centrifuge (Thermo Scientific). The supernatant was labeled “soluble fraction” 
and stored at -20°C. The pellet was resuspended in 1mL NaH2PO4, 300mM NaCl 
solution containing 6M urea to solubilize the pellet, and this mixture was labeled 
“insoluble fraction”. Both fractions were analyzed for target protein expression by 10% 
SDS-PAGE followed by Coomassie brilliant blue staining or western blot. For western 
blot, the presence of target protein’s N-terminal T7·tag®  was detected with biotinylated 
anti-T7·tag
®
 mAb (Merck KGaA) at 20ng/mL followed by streptavidin (SAV) 
conjugated to HRP at 100ng/mL. Films were developed using Pierce ECL western 
blotting substrate (Thermo Scientific). 
 
Purification of Target Proteins 
 Target proteins expressed in the “soluble fraction” were purified by Ni-NTA 
column chromatography using Ni-NTA His·Bind
®  
Resin (Merck KGaA) under native 
conditions. Proteins were eluted using increasing concentration of imidazole in buffer 
(50mM NaH2PO4 and 300mM NaCl, 20-250mM imidazole, pH 8.0). For proteins 
expressed in the “insoluble fraction”, purification was performed in the same way as 
those in the “soluble fraction” under denaturing conditions (6M urea). 1mL fractions 
collected from column chromatography were analyzed for the presence of target protein 
by dot  blotting. The dot blot was probed in the same way as the western blot for the 
T7·tag
®
. Select fractions were then analyzed by 10% SDS-PAGE to determine the purity 
of the sample. Fractions from initial “soluble fraction” that contained the most purified 
target protein were dialyzed into PBS (pH 7.6) and stored at -20°C. For fractions from 
initial “insoluble fraction” that contained the most purified target protein, a stepwise 
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dialysis was performed to remove urea from solution in order to allow refolding of the 
protein. Once dialyzed into buffer without urea (50mM NaH2PO4 and 300mM NaCl), the 
fraction was dialyzed in PBS and stored at -20°C. 
 
Immunization of Rabbits 
 New Zealand White rabbits of at least 3 months of age bred in house were 
immunized with target antigens in TiterMax
®
 Gold adjuvant (Sigma-Aldrich, St. Louis, 
Missouri) by intramuscular and subcutaneous injections. Rabbits were boosted three 
times every two weeks with the same antigen in Freund’s incomplete adjuvant. Blood 
was collected every two weeks throughout the immunization procedure to collect serum. 
Sera were stored at -20°C. All animal protocols were used as per protocols approved by 
the Institutional Animal Care and Use Committee of Loyola University Chicago. 
 
Determination of Antigen-specific Serum Titer  
 The target antigen-specific titer of each serum collected from rabbits was 
determined by enzyme-linked immunosorbance assay (ELISA). Briefly, Costar
®
 96-well 
ELISA plates (Corning, Tewksbury, Massachusetts) were coated with 2μg/mL target 
antigen overnight. Coated plates were blocked with PBS containing 2.5% Difco
TM
 skim 
milk (BD Bioscience) for 2 hours at room temperature, then probed with serial dilutions 
of antigen-specific serum. Antibodies reactive to specific antigens were detected with 
donkey anti-rabbit IgGH+L (heavy and light chains) conjugated to HRP (Jackson 
ImmunoResearch, West Grove, Pennsylvania) at 80ng/mL. The plate was then stained 
with ABTS staining (0.1M sodium citrate buffer pH 4.5, 1.37mg/mL ABTS, 0.015% 
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H2O2) and the absorbance at 405nm using ELx800 Absorbance Microplate Reader 
(BioTek
®
, Winooski, Vermont).  
 
C. difficile S-layer Extraction 
 Overnight culture of C. difficile 630 or BI-17 was prepared in BHI broth. Cells 
were washed in PBS and resuspended in 1mL 200mM glycine buffer, pH 2.2. This 
mixture was incubated for 30 minutes at room temperature and subsequently pelleted by 
centrifugation at 14,000xG for 15 minutes at 4°C. The resulting supernatant containing 
the extracted proteins were dialyzed in PBS and stored at -20°C. The extracted proteins 
were analyzed by 8% SDS-PAGE followed by Coomassie brilliant blue staining.   
 
C. difficile Adhesion Interference Assay 
 Caco-2 BBE cells were grown in Costar
®
 24-well tissue culture plates (Corning) 
until the monolayer reached confluence with high-glucose DMEM (Life Technologies) 
with following additives: 10mM HEPES, 1mM pyruvate, 50U/mL penicillin, 50μg/mL 
streptomycin, 30μg/mL gentamicin, 550μM L-glutamine, 0.0004% 2-mercaptoethanol, 
and 500ng/mL amphotericin B. Once confluent, the monolayer was maintained for three 
additional days. One day before the assay, the medium was switched to DMEM 
supplemented with only 1.5mM CaCl2. Overnight culture of C. difficile was washed and 
resuspended in PBS. 1mL aliquots of C. difficile (diluted to about 6 million colony 
forming units (CFU)/mL) were made and each aliquot was incubated with either naïve or 
serum specific for target antigens for 15 minutes at 36°C at 1:100 dilution. The antibody-
C. difficile mixture was washed once with PBS then resuspended in DMEM with CaCl2. 
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Caco-2 BBE monolayer was introduced into the anaerobic chamber and medium was 
replaced to anaerobic DMEM with 1.5mM CaCl2, 250μL per well. The pre-incubated C. 
difficile mixture was then added to wells 250μL each, achieving about 1.5 x 106 CFU per 
well in 500μL total volume (MOI 1, 1:1 ratio of bacteria:host cells). Bacteria were 
allowed to adhere for 1 hour at 36°C, then the wells were washed twice with 1mL PBS to 
remove non-adherent bacteria. The monolayer was then treated with 1mL PBS containing 
1mM EDTA to disrupt tight junctions, and the entire monolayer was dislodged from the 
well by vigorous pipetting. A relatively homogenous mixture was obtained for each well 
by subsequent vortexing and CFU was determined for each well by plating dilutions onto 
BHI agar plates overnight at 36°C. As a control, adherence interference of C. difficile by 
pre-incubation of cell monolayer with extracted SLPs, as previously reported in the 
literature
61
, was used. Briefly, the medium for the Caco-2 BBE monolayer in a 24-well 
plate was replaced with DMEM containing 1.5mM CaCl2 and 200μg/mL SLP extract, 
250μL per well. The cells were incubated under anaerobic conditions at 36°C for 1 hour 
before C. difficile in DMEM was added to Caco-2 BBE cells at a MOI of 1. Adherence 
was then carried out as outlined above for the antibody assay. 
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CHAPTER THREE 
RESULTS 
Cloning of Target Genes into Expression Vector Constructs 
 From genomic DNA of C. difficile 630, whose genome has been fully sequenced, 
slpA (region coding for HMW SLP), fliD (full length), and cwp84 (region coding for 
mature form) were amplified by PCR to generate vector constructs for expressing target 
proteins. The amplified products were cloned into pET-21a(+) which utilizes a IPTG 
inducible system. After obtaining E. coli clones that gained resistance to ampicillin by the 
transformation of the pET-21a(+) vector constructs, plasmid DNA was analyzed by 
restriction endonuclease digestion with BamHI and XhoI (the sites were introduced into 
target genes by PCR) followed by agarose gel electrophoresis. As shown in Figure 5, 
digestion of plasmid constructs released DNA bands corresponding to expected sizes of 
each target insert, suggesting successful cloning of target genes into the pET-21a(+) 
vector. In order to confirm insert as the intended targets and to check for in-frame cloning, 
the pET-21a(+) constructs were sequenced at the insertion site. Initial attempts at 
sequencing with BigDye
®  
Terminator system (Life Technologies) under standard 
conditions repetitively failed to yield product, and so the lowered extension temperature 
protocol, as suggested in the literature
112
 for AT-rich templates, was used to successfully 
sequence plasmid DNA at the insertion site. The plasmid constructs were confirmed by 
sequencing to be the correct target gene sequences and to be in-frame.
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Figure 5. Restriction digestion analysis of pET-21a(+) expression vector constructs. Each 
vector constructs were digested with BamHI and XhoI for 1 hour then analyzed by 1% 
agarose gel electrophoresis. In lane 2, a band below the 2.0kb mark can be observed 
which corresponds to cwp84 PCR product (about 1.5kb). Also in lane 3, fliD (about 1.5kb) 
can be observed below 2.0kb mark. In lane 4, slpA-HMW SLP (about 1.1kb) can be 
observed below 2.0kb mark and below the 1.5kb bands shown in lane 2 and 3. In lanes 2, 
3, and 4, the pET-21a(+) vector without the insert (about 5.4kb) can be observed between 
the 6.5kb and 4.4kb marks. Some other minor bands are present but likely represent 
undigested plasmid DNA. 
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 The correct plasmid constructs were subsequently transformed into E. coli Rosetta 
2 (DE3) cells. Because this strain of E. coli does not have endA mutations, plasmid 
extraction using standard protocols does not yield quality DNA needed for restriction 
digestion analysis (the DH10B strain we used for cloning contains a single point mutation 
in the endA gene that inactivates the enzymatic activity of the translated protein). In order 
to confirm that the plasmid construct was successfully transformed, colony PCR was 
performed instead. As shown in Figure 6, each expression clone harbors their 
corresponding target gene insert. Along with selection with ampicillin for the presence of 
the pET-21a(+) vector itself, this confirms that correct plasmid constructs were 
transformed successfully into their respective expression host.
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Figure 6. Colony PCR of each E. coli clone transformed with pET-21a(+) expression 
constructs. Each transformed clone of E. coli was probed with three different specific 
primer sets (listed in Table 3) for the presence of target insert. Lanes 5-7 show that the 
Cwp84 clone harbors only cwp84; no bands were found using primers for fliD or slpA in 
this clone. Likewise, lanes 8-10 show fliD specificity in FliD clone and lanes 11-13 show 
the same for HMW SLP clone. No bands are found in lanes 2-4 in which no template was 
added to reaction mixture.
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Expression of Target Proteins 
 E. coli clones harboring the expression plasmid constructs were tested for their 
ability to express target proteins. Initially, the expression plasmid constructs were 
transformed into E. coli BL21 (DE3) cells (Merck KGaA), a standard strain for 
recombinant protein expression. However, only Cwp84 was successfully expressed using 
this system, while the induction experiments under various conditions repetitively failed 
to produce FliD and HMW SLP. C. difficile genomic DNA is known to be rich in AT 
content, and thus quite different from the genomic DNA content of E. coli. The problem, 
in the context of recombinant protein production, is that C. difficile proteins utilize 
codons that are relatively rare in E. coli since E. coli does not utilize those codons much 
for producing its own proteins. This codon bias results in truncated proteins or even early 
translational termination which leads to poor or no protein yield. To address the issue of 
codon bias, the expression host strain was switched to E. coli Rosetta 2 (DE3) cells, 
which possess a pRARE2 plasmid which encodes tRNA genes rare in E. coli, essentially 
supplementing the host with rare codons. As shown in Figure 7A, induced lysates of each 
of the clones have T7 tagged target proteins which indicate successful expression. The 
Cwp84 previously expressed from the BL21 strain was used as a positive control here, 
and it can be observed that Cwp84 expression level is much greater in the Rosetta 2 strain. 
Thus, subsequent production of Cwp84 was performed using the Rosetta 2 clone instead.
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Figure 7. Analysis of induced E. coli Rosetta 2 (DE3) expression hosts for expressed 
proteins. A. Western blot analysis for expressed proteins. Uninduced and induced E. coli 
clone lysates were analyzed for the presence of T7·Tag
®  
which is on the N-terminus of 
expressed protein construct. HMW SLP (about 45kD), FliD (about 53kD) and Cwp84 
(about 50kD) clones show bands at correct respective sizes. The Cwp84 lane is difficult 
to visualize due to overpowering signal, but the major banding seems to be ~50kD. SDS-
PAGE analysis as shown in Figure 7B supports Cwp84 band ~50kD. Uninduced lysates 
do not show any bands. (+): control T7 tagged protein. B. SDS-PAGE analysis of 
expressed proteins. Induced lysates were separated into insoluble and soluble fractions 
and analyzed in separate lanes. For Cwp84, only the insoluble fraction was analyzed. (-): 
uninduced sample. (+): induced sample. Box indicates the expected band sizes for each 
target proteins.
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 Because the purification process for the expressed proteins differ based on the 
solubility state of the molecule, a SDS-PAGE analysis was performed for the lysates that 
were separated into soluble and insoluble fractions. If the protein is expressed as a 
soluble protein, purification is performed under native conditions while if the protein is 
insoluble, the expressed protein need to be denatured during purification and 
subsequently be refolded into native conditions. As observed from previous work in the 
BL21 strain (data not shown), Cwp84 was produced only in the insoluble fraction when 
expressed in the Rosetta 2 strain. As for FliD and HMW SLP, the majority of the 
expressed proteins are in the soluble fraction while a lesser amount are produced as 
insoluble inclusion bodies, indicated in Figure 7B by the darker band staining in the 
soluble fraction sample than the insoluble fraction. Therefore, FliD and HMW SLP was 
determined to be purified from the soluble fraction using native conditions while Cwp84 
was determined to be purified from the insoluble fraction using denaturing conditions. 
  
Purification of Target Proteins 
 The pET-21a(+) vector construct encodes a C-terminal hexahistidine tag (6x His), 
which has affinity to certain metal ions such as Ni
2+
. Thus, the expressed proteins, 
possessing the C-terminal 6x His tag, were purified from E. coli lysates by Ni-NTA 
column chromatography. Column fractions (1mL) were collected and each fraction was 
tested for the presence of the T7·Tag
®  
by dot blot to determine which fractions contain 
the target proteins. One representative dot blot (for FliD) is shown in Figure 8. As shown 
in Figure 8, the presence of the fusion tagged proteins in the flow-through fractions 
indicate that some expressed target proteins did not bind to column. Only minimal 
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amounts of target protein eluted during the wash fractions. Strong signals for the T7·Tag
®  
can be observed in the first few fractions of the elution fractions, indicating that the 
majority of target proteins eluted in those first few fractions. 
 The dot blot analysis reveals the presence of the target proteins, but it does not 
measure the relative purity of the proteins. To determine the degree of protein 
purification, SDS-PAGE analysis of select fractions was performed. As shown in Figure 
9A, there is a decrease in the number of bands present in the fraction beginning with the 
initial, unpurified sample to purified elutions, indicating that the target protein was 
selectively purified from the lysate. The same purification procedure was followed for the 
other two target proteins HMW SLP and Cwp84, although with Cwp84 purification 
followed denaturing conditions containing 6M urea since it was expressed as insoluble 
proteins. Figure 9B shows the purified proteins analyzed by SDS-PAGE. Interestingly, 
HMW SLP and Cwp84 both show major co-purifying bands. If contaminating E. coli 
proteins were present in the purified fractions, the co-purifying bands would be of similar 
size across samples since ones that have affinity to Ni
2+
 would have bound to column. 
However, the co-purifying bands are different in HMW SLP and Cwp84 purification, 
indicating that degradation products of target proteins during expression are causing these 
extra bands. This was later supported by western blot analysis where antibodies raised 
against each purified sample did not cross-react against each other, indicating that the co-
purified bands are not shared between the samples (data not shown).
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Figure 8. Representative dot blot analysis of Ni-NTA fractions (FliD). Flow-through 
samples represent fractions collected without imidazole. Wash samples were collected in 
the presence of 20mM imidazole (20 Wash), or with 50mM imidazole (50 Wash). Elution 
samples were collected in the presence of 250mM imidazole, and the clean samples were 
collected with 1M imidazole to elute any remaining proteins. Starting material is the 
sample loaded onto the column. The blot was probed for the presence of T7·Tag
®
. SW: 
first fraction collected immediately after switching buffer.
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Figure 9. Purification of target proteins by Ni-NTA column chromatography. A: 
Representative SDS-PAGE analysis of select Ni-NTA fractions (FliD). B: SDS-PAGE 
analysis of target protein elution fractions containing the most protein. HMW SLP 
(~45kD), Cwp84 (~50kD), FliD (~53kD). Gels were all stained with Coomassie Brilliant 
Blue.
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Generation of Target Antigen-specific Serum 
 Purified target proteins were used as immunogens in rabbits to produce antigen-
specific antisera. To determine if the rabbits immunized with the antigen indeed 
generated antigen-specific antibodies, sera were collected at various points throughout 
the immunization protocol and their reactivity to respective immunogens was tested by 
ELISA. As shown in Figure 10, there is a significant increase in absorbance in the serum 
collected from immunized rabbits compared to naïve serum; in Figure 10, one 
representative pre-immune serum (from the FliD-immunized rabbit) is shown, though it 
was confirmed that all immunized sera resulted in increased absorbance compared to pre-
immune serum from other rabbits (data not shown). Also, in other ELISA and western 
blot analyses where sera were tested against antigens other than the respective 
immunogens, such as anti-FliD antiserum against recombinant HMW SLP, no cross-
reactivity was observed, indicating that the produced antisera were indeed target antigen-
specific (data not shown). 
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Figure 10. Production of target antigen-specific antisera from rabbits. Sera from rabbits 
were collected after the final booster injection and analyzed for reactivity against 
respective antigens by ELISA. Sera were serially diluted 1:2 from 1:1,000 to 1:1,024,000. 
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Adherence Interference 
 To test if antibodies against FliD, HMW SLP, and Cwp84 could block C. difficile 
adherence in vitro, an adherence interference assay with Caco-2 BBE cells was 
performed. Caco-2 BBE cells are brush-border expressing epithelial cell line of colonic 
origin, and serve as an in vitro model for the GI tract epithelial surface to where C. 
difficile may initially bind during CDI pathogenesis. Thus, if the target antibodies can 
interfere with C. difficile adherence, the adherence of C. difficile pre-incubated with 
target-molecule specific antiserum should be decreased compared to those treated with 
naïve serum. The adherence interference assay was performed, and no significant 
decrease in adherence in C. difficile treated with immune serum compared to naïve serum 
was observed as shown in Figure 11. Only one group reached statistically significant 
decrease in group pre-treated with all three antisera, but as none of the individual 
components achieved significant decrease in C. difficile adherence, it seems likely that 
the antibodies targeting FliD, HMW SLP, and Cwp84 do not affect C. difficile adherence 
to Caco-2 BBE monolayers.  
 Interestingly, when Caco-2 BBE monolayers were pre-treated with S-layer 
extracts for 1 hour, the subsequent adherence of C. difficile significantly increased as 
shown in Figure 11. In the literature, C. difficile SLPs were described as adhesins as the 
S-layer extract was shown to decrease C. difficile adherence to Hep-2 cells and also 
found to be in proximity of human GI tract sections
61
. As such, the SLP pre-treatment of 
Caco-2 BBE cells were tested essentially as a positive control for this system. However, 
in Caco-2 BBE cells which express brush borders, a characteristic of GI tract epithelium, 
the SLPs seem to have the opposite effect. This suggests that while SLPs are still 
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potential adhesins, they may not serve a major function in C. difficile adherence to Caco-
2 BBE cells. Similarly, antibodies directed against FliD and Cwp84 also do not affect C. 
difficile adherence significantly, indicating that these molecules also may not play a role 
in adherence to Caco-2 BBE cells. 
 It was demonstrated that environmental factors such as divalent cations have 
dramatic effects in C. difficile adherence
78
. Divalent cations are a crucial component of 
cellular physiology, thus in vitro culture media are often supplemented with a calcium 
source, typically serum. In serum-free media, as used in this C. difficile adherence 
interference assay, calcium chloride is added as a source of divalent cation 
supplementation. Taking into account the report in which high levels of CaCl2 (up to 
25mM) in solution increased C. difficile adherence to Vero cells by 13 to 17-fold
78
, the 
effect of Ca
2+
 on C. difficile adherence interference in Caco-2 BBE cells was investigated. 
When no exogenous calcium was added to the medium, the adherence interference of C. 
difficile to Caco-2 cells by target antibodies did not differ significantly from the data 
shown in Figure 11 (performed with 1.5mM CaCl2), suggesting that soluble levels of 
Ca
2+
 did not affect adherence interference by target antibodies. Typically, Ca
2+
 is 
supplied to the medium at concentrations below 1.7mM CaCl2 due to its poor solubility 
in media containing abundant phosphate and carbonate ions. Nevertheless, 25mM CaCl2 
supplementation in DMEM for the C. difficile adherence interference assay was 
attempted. While this resulted in significant increase in overall adherence levels (data not 
shown), precipitates forming in the medium may have caused this increase in adherence. 
Thus, the assay was subsequently performed with only soluble levels of CaCl2 also 
because the absence of calcium may affect the monolayer detrimentally.
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Figure 11. C. difficile adherence interference assay with rabbit antisera against target 
proteins. % adherence was calculated by dividing the number of CFU C. difficile 
recovered by the number of CFU initially added to wells and multiplying by 100. All % 
adherence was normalized to C. difficile-only samples. Data pooled from seven different 
experiments, normalized to percent adherence of C. difficile alone group in each 
experiment. Total sample size (N): C. difficile alone – 17, SLP Pre-treatment – 11, Naïve 
serum – 3, α-HMW SLP – 3, α-FliD – 3, α-Cwp84 – 3, Pooled antisera – 11. Statistical 
analysis was performed using two-tailed student’s t-test at α=0.05.
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CHAPTER FOUR 
DISCUSSION 
Vaccines and Colonization Resistance 
 CDI is the major cause of hospital-acquired infectious diarrhea, and its treatment 
remains a heavy burden to healthcare systems and a difficult challenge for physicians. As 
shown in animal and epidemiological studies, exposure to antibiotics leads to severe 
alterations of the gut microbiota, and it is the major risk factor for contracting CDI
4
. Even 
though antibiotics cause CDI, they are also used to treat CDI. Consequently, the 
microbiota is still left disrupted for C. difficile to take foothold again and cause recurrent 
CDI. 
 Several new therapies in development seek to address the issue of recurrent 
disease. As described in Table 1, new antibiotics have narrower spectrum and cause a 
relatively mild alteration of the gut microbiota, and fecal transplantation seeks to restore 
the microbiota altered by CDI or antibiotic therapy. Both therapies focus on the 
importance of normal gut microbiota, as it provides colonization resistance against C. 
difficile. If the microbial balance can be maintained during antibiotic therapy, or be re-
established, recurrent CDI can be prevented through colonization resistance. 
 Vaccines for CDI have been in development for a while, but most success has 
come from targeting TcdA and TcdB, aiming to induce an anti-toxin antibody response in 
the host. While antibodies against toxins have been shown in both animal studies and in
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preliminary human trials to have protective effects in CDI, it is suggested that such 
response does not prevent colonization with C. difficile
11
. As such, an individual 
successfully vaccinated to generate a neutralizing anti-TcdA/TcdB antibody response 
may be asymptomatically colonized, and may still shed infectious spores into the 
environment where another individual may contact. If an immune response were 
generated that confers colonization resistance against C. difficile in individuals, the 
spread of infectious spores could be prevented. Potential for vaccines that could induce 
an immune response that confers colonization resistance have thus been investigated in 
this study. 
 
C. difficile Adherence to Host GI Tract Mucosa 
 Bacterial adherence to host gut mucosal surface is a complex process involving 
many different factors such as physical mechanics, protein-protein interactions, and 
others. For example, both the bacterial cell membrane and the mammalian epithelial cell 
membrane is made of a lipid bilayer. The lipid bilayer is kept electrically polarized by the 
cells and thus the bacteria must overcome charge-mediated repulsive to get in proximity 
with the host cell. Once this barrier is overcome, specific interactions between the host 
and the bacteria including adhesin-receptor complexes can mediate tight adhesion 
processes. However, the dynamic process that is bacterial adherence to host mucosal 
surface is more complex. This is partly due to the nature of the host gut mucosa, 
consisting of a heterogeneous population of cells that form the epithelial barrier such as 
specialized M cells and goblet cells, immune components that constantly interact with the 
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mucosa, and even minor damage that occurs in the epithelium that can cause potentially 
significant changes to the mucosa. 
 In the case of C. difficile, literature suggests that the nature of C. difficile 
adherence to host gut mucosa is also complex. While the initial studies suggested that C. 
difficile associates with the apical tip of the brush borders on differentiated Caco-2 cells
81
, 
another study suggested that C. difficile binding to Caco-2 cells decrease significantly 
upon differentiation of the Caco-2 cells when the brush border expression would 
increase
82
. The latter study suggested that the extracellular matrix is also involved in C. 
difficile adherence. In addition, C. difficile flagella can bind to mucus
53
 which is yet 
another surface in the gut mucosa that the bacteria can interact with. Because in vitro cell 
line models cannot provide all of the components of the gut mucosal surface, the in vivo 
significance of the data on adherence studies are still difficult to interpret in the context 
of in vivo pathogenesis. 
 
Models and Adherence Assays 
  The adherence interference assay with the Caco-2 BBE monolayer seems to 
suggest that antibodies against HMW SLP, FliD, and Cwp84 fail to interfere with C. 
difficile adherence. This is inconsistent from the published data which suggests that 
HMW SLP and FliD work as adhesins in vitro. In the case of Cwp84, the molecule is not 
an adhesin but is involved in SlpA processing
68
, and thus antibody binding may lead to 
disrupted S-layer function. While there may be multiple factors that contribute to this 
discrepancy, one deviation of this experiment from the literature is the use of a different 
cell line. Studies of C. difficile adherence have been initially performed with Caco-2 
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cells
81
, as it is a cell line derived from human colonic origin and expresses qualities 
resembling enterocytes that line the intestine
110
. However, published studies of C. difficile 
adhesins were not done using Caco-2 cells. FliD was originally identified as an adhesin 
using radiolabeled Vero cells, an epithelial cell line of kidney origin that bound to 
immobilized FliD
53
. SLPs were identified as adhesins in studies showing that S-layer 
extract mediated adherence interference of C. difficile using Hep-2 cells
61
, an epithelial 
cell line derivative of HeLa cells. At the same time, IgY(major antibody class found in 
chicken egg yolk) specific for FliD and Cwp84 was shown to decrease C. difficile 
adherence in T84 cells that are metastatic colon cancer cells from the lung
72
. As for SLPs, 
acid-extracted SLPs were also found to be associated with the epithelium of human GI 
tract tissue sections
61
, though no adherence studies with C. difficile were performed with 
these tissue sections. Additionally, studies of ΔfilD mutant and ΔfbpA mutant showed 
that adherence is increased in the absence of these potential adhesion molecules
26, 89
 
which also makes the role these molecules play in adherence unclear. Along with the data 
from Caco-2 BBE epithelial model, the data seem to suggest that antibodies against FliD, 
HMW SLP, and Cwp84 can block adherence in some models but not in others. Adding to 
this issue, FliD can bind mucus
53
 while HMW SLP can bind to certain ECM proteins
61
, 
which complicates the matter deciding which binding activity is actually more important 
for C. difficile adherence to mucosa. In vitro models of bacterial adherence do not 
provide all possible components to which C. difficile may bind, nor can such an approach 
easily address the issue of determining which mechanism contributes more than another. 
Overall, the failure of the antibodies against FliD, HMW SLP, and Cwp84 to block 
adherence in Caco-2 BBE cells highlight the need to recognize that results from one in 
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vitro model may not be reproduced in other models. Thus, a different model that better 
simulates the in vivo conditions is needed to confirm the adhesion activity of target 
molecules and to test if antibodies can block adherence and subsequent colonization. 
Some possible models are ex vivo gut mucosal tissue sections to determine if antibodies 
block adherence of C. difficile to gastrointestinal mucosa directly and using in vivo 
animal model to determine if antibodies can reduce colonization of animal host with C. 
difficile. 
 
Alternative Approaches to CDI Vaccines 
 While the interference of adherence can be a mechanism on which antibodies 
against C. difficile surface molecules could protect one from CDI, there are other possible 
mechanisms by which the antibodies may protect. Thus, antibodies that do not block C. 
difficile adherence may still protect individuals from CDI. One example demonstrating 
potential protection employs passive immunization of hamsters using antibodies against 
SLPs
74
. In this study, all hamsters immunized with C. difficile became colonized but 
survival was prolonged in immunized hamsters compared to unimmunized hamsters. This 
suggested that the antibodies conferred slight resistance to disease in hamsters. While the 
level of colonization was not determined in this study, C. difficile pre-incubated with 
anti-SLPs antiserum showed enhanced uptake by THP-1 cells, a human phagocytic 
monocyte cell line, in vitro. This indicated that the antibodies opsonized C. difficile for 
enhanced uptake by THP-1 cells. While protection was modest at best,  and it was 
unclear if opsonization did play a role in vivo to provide that protection, the study showed 
that effective opsonization of C. difficile with antibodies can contribute to protection 
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against CDI. Additionally, enhanced uptake of C. difficile can contribute to enhanced 
antigen presentation to the adaptive immune system which in turn could enhance 
protection. To date, only few opsonization studies with C. difficile have been reported. 
Further studies are required to identify which antigens, when targeted by antibodies, 
induce opsonization that could enhance host protection. 
 Many potential targets for vaccine development remain to be tested, including 
molecules involved in pathogenesis and those yet to be discovered. As illustrated in 
Figure 12, there are multiple mechanisms by which C. difficile interact with the host gut 
mucosa that can potentially be targeted by vaccines for protection. The adherence of C. 
difficile to gut mucosa, if blocked efficiently by antibodies, could protect one from 
colonization. If C. difficile uptake by phagocytic cells can be enhanced by antibodies, it 
may also lead to enhanced protection from CDI. It is also known that epithelial cells 
harbor receptors that mediate bidirectional transport of antibodies and its antigens across 
the epithelium. These mechanisms are capable of transporting in opsonized bacteria for 
enhanced immune recognition or transporting invading bacteria out from the lamina 
propria to the gut lumen, potentially contributing to protection. There may be additional 
mechanisms in which a vaccine could protect such as mechanisms involving complement 
activation or other novel mechanisms, but further studies are required to test this 
possibility.  
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Figure 12. Illustration of known C. difficile-host interaction pathways that have potential 
for vaccine development. Blocking of C. difficile interaction with mucus, epithelial 
surface, or ECM proteins may interfere with colonization. Alteration of C. difficile uptake 
by antigen presenting cells (APC)  or transcytosis through the epithelial barrier could 
expose bacteria to immune system. 
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Concluding Remarks 
 Prevention and treatment of CDI is a major challenge for healthcare systems. 
Because it is initiated by the disruption of the microbiota through antibiotics, CDI 
represents a call to develop novel therapeutics that take into consideration a previously 
underappreciated aspect of mammalian biology, the microbiota. Vaccines have the 
potential to prevent the spread of CDI by preventing colonization that can last an 
individual’s lifetime given an effective immunization strategy. Many candidate molecules 
have been identified for vaccine development to prevent CDI, but the complexity of C. 
difficile interaction with the host gut mucosal environment presents a challenge to 
extrapolate the current in vitro findings for in vivo significance. In this work, antibodies 
against FliD, HMW SLP, and Cwp84, molecules suggested in the literature to be 
involved in C. difficile adherence, were tested for their ability to reduce C. difficile 
adherence to Caco-2 BBE cell line, a model for gut intestinal epithelium not described 
previously in studies of C. difficile adherence interference. The antibodies failed to 
significantly reduce C. difficile adherence in this model which suggest that antibody-
mediated adherence inhibition may be dependent upon different assay conditions. There 
are many more vaccine candidates to be tested and discovered including those that may 
confer protection through mechanisms not involving adherence. The data here highlight a 
need to study different, alternative models of C. difficile interactions with host mucosa in 
order to identify and test vaccine potential of molecules and mechanisms yet to be 
discovered.
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